“Long-Term Safety and Effectiveness of Adalimumab for Moderat-to-Severe Psoriasis: Results from the Eight-Year Interim Analysis of the ESPIRIT Registry”, J of Skin, vol. 1, no. 3.1, p. s22, Oct. 2017, doi: 10.25251/skin.1.supp.21.